FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066471812> ?p ?o ?g. }

• W2066471812 endingPage "7147" @default.
• W2066471812 startingPage "7142" @default.
• W2066471812 abstract "Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2/ErbB-2), has become the mainstay of treatment for HER2-positive breast cancer. Nevertheless, its exact mechanism of action has not been fully elucidated. Although several studies suggest that Fc receptor-expressing immune cells are involved in trastuzumab therapy, the relative contribution of lymphocyte-mediated cellular cytotoxicity and antitumor cytokines remains unknown. We report here that anti-ErbB-2 mAb therapy is dependent on the release of type I and type II IFNs but is independent of perforin or FasL. Our study thus challenges the notion that classical antibody-dependent, lymphocyte-mediated cellular cytotoxicity is important for trastuzumab. We demonstrate that anti-ErbB-2 mAb therapy of experimental tumors derived from MMTV-ErbB-2 transgenic mice triggers MyD88-dependent signaling and primes IFN-γ-producing CD8+ T cells. Adoptive cell transfer of purified T cell subsets confirmed the essential role of IFN-γ-producing CD8+ T cells. Notably, anti-ErbB-2 mAb therapy was independent of IL-1R or IL-17Ra signaling. Finally, we investigated whether immunostimulatory approaches with antibodies against programmed death-1 (PD-1) or 41BB (CD137) could be used to capitalize on the immune-mediated effects of trastuzumab. We demonstrate that anti-PD-1 or anti-CD137 mAb can significantly improve the therapeutic activity of anti-ErbB-2 mAb in immunocompetent mice." @default.
• W2066471812 created "2016-06-24" @default.
• W2066471812 creator A5007330428 @default.
• W2066471812 creator A5010278367 @default.
• W2066471812 creator A5034127914 @default.
• W2066471812 creator A5040640951 @default.
• W2066471812 creator A5047414830 @default.
• W2066471812 creator A5054642059 @default.
• W2066471812 creator A5061575707 @default.
• W2066471812 creator A5070494006 @default.
• W2066471812 date "2011-04-11" @default.
• W2066471812 modified "2023-10-16" @default.
• W2066471812 title "Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy" @default.
• W2066471812 cites W1528349069 @default.
• W2066471812 cites W1531206210 @default.
• W2066471812 cites W1978354618 @default.
• W2066471812 cites W2006471464 @default.
• W2066471812 cites W2010121426 @default.
• W2066471812 cites W2021588881 @default.
• W2066471812 cites W2027542837 @default.
• W2066471812 cites W2042190557 @default.
• W2066471812 cites W2049678425 @default.
• W2066471812 cites W2051122657 @default.
• W2066471812 cites W2061982934 @default.
• W2066471812 cites W2062889582 @default.
• W2066471812 cites W2080595933 @default.
• W2066471812 cites W2089071484 @default.
• W2066471812 cites W2097931076 @default.
• W2066471812 cites W2097964229 @default.
• W2066471812 cites W2103118255 @default.
• W2066471812 cites W2107426197 @default.
• W2066471812 cites W2109550365 @default.
• W2066471812 cites W2110250476 @default.
• W2066471812 cites W2114101532 @default.
• W2066471812 cites W2115175735 @default.
• W2066471812 cites W2117984780 @default.
• W2066471812 cites W2122080125 @default.
• W2066471812 cites W2127276356 @default.
• W2066471812 cites W2128402413 @default.
• W2066471812 cites W2130153302 @default.
• W2066471812 cites W2133105825 @default.
• W2066471812 cites W2136364651 @default.
• W2066471812 cites W2142287133 @default.
• W2066471812 cites W2164361217 @default.
• W2066471812 cites W2170231371 @default.
• W2066471812 doi "https://doi.org/10.1073/pnas.1016569108" @default.
• W2066471812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3084100" @default.
• W2066471812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21482773" @default.
• W2066471812 hasPublicationYear "2011" @default.
• W2066471812 type Work @default.
• W2066471812 sameAs 2066471812 @default.
• W2066471812 citedByCount "397" @default.
• W2066471812 countsByYear W20664718122012 @default.
• W2066471812 countsByYear W20664718122013 @default.
• W2066471812 countsByYear W20664718122014 @default.
• W2066471812 countsByYear W20664718122015 @default.
• W2066471812 countsByYear W20664718122016 @default.
• W2066471812 countsByYear W20664718122017 @default.
• W2066471812 countsByYear W20664718122018 @default.
• W2066471812 countsByYear W20664718122019 @default.
• W2066471812 countsByYear W20664718122020 @default.
• W2066471812 countsByYear W20664718122021 @default.
• W2066471812 countsByYear W20664718122022 @default.
• W2066471812 countsByYear W20664718122023 @default.
• W2066471812 crossrefType "journal-article" @default.
• W2066471812 hasAuthorship W2066471812A5007330428 @default.
• W2066471812 hasAuthorship W2066471812A5010278367 @default.
• W2066471812 hasAuthorship W2066471812A5034127914 @default.
• W2066471812 hasAuthorship W2066471812A5040640951 @default.
• W2066471812 hasAuthorship W2066471812A5047414830 @default.
• W2066471812 hasAuthorship W2066471812A5054642059 @default.
• W2066471812 hasAuthorship W2066471812A5061575707 @default.
• W2066471812 hasAuthorship W2066471812A5070494006 @default.
• W2066471812 hasBestOaLocation W20664718121 @default.
• W2066471812 hasConcept C109316439 @default.
• W2066471812 hasConcept C121608353 @default.
• W2066471812 hasConcept C126322002 @default.
• W2066471812 hasConcept C159654299 @default.
• W2066471812 hasConcept C202751555 @default.
• W2066471812 hasConcept C203014093 @default.
• W2066471812 hasConcept C2779251935 @default.
• W2066471812 hasConcept C2779786085 @default.
• W2066471812 hasConcept C2780249625 @default.
• W2066471812 hasConcept C502942594 @default.
• W2066471812 hasConcept C530470458 @default.
• W2066471812 hasConcept C542903549 @default.
• W2066471812 hasConcept C55493867 @default.
• W2066471812 hasConcept C71924100 @default.
• W2066471812 hasConcept C86803240 @default.
• W2066471812 hasConcept C8891405 @default.
• W2066471812 hasConceptScore W2066471812C109316439 @default.
• W2066471812 hasConceptScore W2066471812C121608353 @default.
• W2066471812 hasConceptScore W2066471812C126322002 @default.
• W2066471812 hasConceptScore W2066471812C159654299 @default.
• W2066471812 hasConceptScore W2066471812C202751555 @default.
• W2066471812 hasConceptScore W2066471812C203014093 @default.
• W2066471812 hasConceptScore W2066471812C2779251935 @default.
• W2066471812 hasConceptScore W2066471812C2779786085 @default.

• next